Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial

This study should provide evidence of the potential benefits of liraglutide (maximum dosage 3.0  mg daily) on body weight and metabolic variables in people with schizophrenia, schizoaffective disorder and first-episode psychosis. It will also address the feasibility and acceptability of the use of liraglutide in mental health settings. This will inform the design of a longer outcome study th at will be needed to determine whether any weight loss can be maintained in the long term.Trial registrationUniversal Trial Number (UTN), ID:U1111-1203-0068. Registered on on 2/10/2017.European Clinical Trials Database (EudraCT), ID:2017-004064-35. Registered on 3/10/2017.
Source: Trials - Category: Research Source Type: clinical trials